Companies Dominating the Genetic Cardiomyopathies Market
- Becton Dickinson and Company
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis International AG
- Merck & Co.
- Teva Pharmaceuticals Industries Ltd.
- Bristol Myers Squibb Company
- Mylan N.V.
- Boston Scientific Corporation
- Critical Care Diagnostics Inc.
- Bio-Rad Laboratories Inc.
- Sanofi S.A
- Roche Holding AG
- Astella Pharma
Browse Key Market Insights with Data Illustration:
In the News
- April 2023: Bristol Myers Squibb announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) suggested approval of CAMZYOS® (mavacamten) for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (HCM) in adult patients. The European Commission (EC), which has the competence to approve medicines for the European Union (EU), will now assess the CHMP opinion.
- July 2023: Novartis AG has revealed that the US Food and Drug Administration (FDA) has authorized a label update for Leqvio® (inclisiran) to allow for earlier usage as an addition to diet and statin therapy in patients with elevated LDL-C who are at increased risk of heart disease1. This patient group comprises patients with comorbidities such as hypertension and diabetes who have not yet experienced their first cardiovascular event. Leqvio is the first and only small interfering RNA (siRNA) medication to decrease LDL-C, and it was approved by the FDA in December 2021.
